Literature DB >> 6979270

Blood disoprofol levels in anesthetised patients. Correlation of concentrations after single or repeated doses with hypnotic activity.

H K Adam, B Kay, E J Douglas.   

Abstract

The blood concentrations of disoprofol (Diprivan) after single intravenous doses of 1, 2 or 3 mg/kg have been examined in a subpopulation from previously reported clinical studies. The linear relationship between sleep time and dose could be explained by the linearity of the pharmacokinetics at these doses. After a single injection the awakening concentration was independent of dose, with a mean value of 1.04 micrograms/ml. No acute tolerance occurred with disoprofol. On repeated 1 mg/kg bolus injections the sleeping time rose initially but stabilised after four doses. The waking concentration was independent of the number of doses administered. The clinical findings fitted an agent with a very rapid distribution phase and a short elimination half-life.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979270     DOI: 10.1111/j.1365-2044.1982.tb01223.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

1.  Propofol for sedation in a mentally retarded dental patient.

Authors:  J A Roelofse; P van der Bijl
Journal:  Anesth Prog       Date:  1994

Review 2.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability.

Authors:  G Levy
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

4.  Extended blood collection period required to define distribution and elimination kinetics of propofol.

Authors:  G A Campbell; D J Morgan; K Kumar; D P Crankshaw
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

Review 5.  The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.

Authors:  P J Williams; E I Ette
Journal:  Clin Pharmacokinet       Date:  2000-12       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of the newer intravenous anaesthetic agents.

Authors:  P J Davis; D R Cook
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 7.  Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic.

Authors:  M S Langley; R C Heel
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 8.  Anaesthesia for coronary artery surgery--a plea for a goal-directed approach.

Authors:  R I Hall
Journal:  Can J Anaesth       Date:  1993-12       Impact factor: 5.063

Review 9.  Pharmacokinetic implications for the clinical use of propofol.

Authors:  J Kanto; E Gepts
Journal:  Clin Pharmacokinet       Date:  1989-11       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.